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Introduction {#sec001}
============

Amorphous silica nanoparticles from natural sources \[[@pone.0223339.ref001]\] and at workplaces are common in ambient air. Upon breathing, the nanoparticles (\<0.1 μm, also termed ultrafine particles) reach the alveolar region of the lung to an increasing extent with decreasing size and are mainly deposited in the alveolar region \[[@pone.0223339.ref002]\]. Unlike crystalline silica that can cause silicosis, chronic obstructive pulmonary disease (COPD), and lung cancer \[[@pone.0223339.ref003],[@pone.0223339.ref004]\], amorphous silica is quickly cleared, potentially explaining why it has few if any pathologic effects \[[@pone.0223339.ref005]\]. A detailed kinetic study in rats using silica-coated as well as other radiolabeled nanoparticles reported a biphasic clearance from the lung with a t~1/2~ of only 0.2--0.3 hours for the first phase and t~1/2~ of 1.2 days for the second phase, leading to complete clearance \[[@pone.0223339.ref006]\]. Another study found a large range of nanoparticles with noncationic surface charges to be rapidly translocated from the lung lumen to the mediastinal lymph nodes \[[@pone.0223339.ref007]\]. The speed and efficiency of clearance for these particles are inconsistent with removal by alveolar macrophages \[[@pone.0223339.ref008]\] that takes weeks to years to complete \[[@pone.0223339.ref009],[@pone.0223339.ref010]\]. As well, particles within macrophages leave the lung via the mucociliary pathway. For alveolar particles to rapidly reach the lymph and blood implies that they first cross the epithelium.

Here we show by intravital microscopy in mice how particles settle on the alveolar wall in agglomerates and are then removed from the area at a rate consistent with the published kinetics for these and similar nanoparticles. Electron microscopy of the lungs show the agglomerates in stages of crossing the alveolar epithelium: Particles adhered to the epithelium, inside the epithelial cells in large compartments, or in the interstitium. The process appears geared towards agglomerates but also occurs for individual particles. Note that agglomerates are the predominant form for nanoparticles in aerosols and in liquids \[[@pone.0223339.ref011]\].

The novel pathway, described in this paper, constitutes a key advance in understanding inhalation toxicology and clearance of nanoparticles. Considering access to the transepithelial pathway may also be relevant to inhalation drug design.

Materials and methods {#sec002}
=====================

Materials {#sec003}
---------

Fluorescent (red and infrared, [Table 1](#pone.0223339.t001){ref-type="table"}) amorphous silica particles of 50 nm in size were purchased from Kisker Biotech (Steinfurt, Germany). Silica nanoparticles with a size of 58 nm and silver core of 28 nm were obtained from nanoComposix (San Diego, USA). Nanopowder of titanium (IV) dioxide (contains 1% Mn as dopant, nanopowder, \<100 nm particle size (BET), ≥97%), sodium azide (NaN~3~), and 2-deoxy-D-glucose were purchased from Sigma-Aldrich (Oakville, Canada), perfluorocarbon FC-43 (PFC) was obtained from 3M (London, Canada).

10.1371/journal.pone.0223339.t001

###### Nanoparticles and concentrations used *in vivo*.

![](pone.0223339.t001){#pone.0223339.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Experiment                   Particle\            Diameter\     Fluorescence\   Conc\     mg/kg\   μg/\
                               (Abbreviation)       (nm)          (Ex / Em)       (mg/ml)   μg/gm    animal[\*](#t001fn001){ref-type="table-fn"}
  ---------------------------- -------------------- ------------- --------------- --------- -------- ---------------------------------------------
  **Intravital**               Silica\              50            Red\            0.5       3.8\     76\
                               (S50-Red)                          (569 / 585)                        

  **Isolated organ Imaging**   Silica\              50            Infrared\       9         36       720
                               (S50-IR)                           (754 / 778)                        

  **Electron microscopy**      Silica w/ Ag core\   58            None            1.0       3.0\     60\
                               (S-Ag)                                                                

  Silica\                      50                   Red\          0.95            3.8       76       
  (S50-Red)                                         (569 / 585)                                      

  Silica\                      50                   Red\          0.05            0.15      3        
  (S50-Red)                                         (569 / 585)                                      

  TiO2 1% Mn doped\            \<100                None          0.5             3.8\      76       
  (TiO2-Mn)                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------

\*Average animal was 20g.

Intravital imaging {#sec004}
------------------

We adapted a protocol \[[@pone.0223339.ref012]\]. for inverted lung microscopy to now include partial liquid ventilation. Female C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME) and used between 8 and 16 weeks of age. The entire protocol (no. AC13-0105) was approved by the University of Calgary Animal Care Committee. Mice were anesthetized with ketamine (150 μg/g body weight) and xylazine (10 μg/g body weight) i.p and the jugular vein was cannulated for further central access. Tracheotomy was performed and a ventilation cannula (outer diameter 1.2 mm, inner diameter 0.8 mm) was inserted into the trachea and secured around the lower front teeth with sutures. Inside the cannula, PE-10 tubing was inserted into the cannula to facilitate administration of nanoparticles, while, at the same time, ventilating the mouse. Ventilation was performed at 120 breaths per minute, a stroke volume of 200 μl, and a positive-end expiratory pressure (PEEP) of 3 cm H~2~O. Mice were laid in the lateral decubitus position on the right side and the thorax was opened for direct access to the lung \[[@pone.0223339.ref012]\]. A thoracic suction window with a 12 mm coverslip (\#1.5) was placed in a custom-built microscopy stage holder and the lung was restrained from moving with a vacuum of around 130 mm Hg. The mouse stage was turned upside down and placed on an inverted Nikon A1plus microscope on a 40x water-immersion objective (NA 1.15) with a resonance scanner. After focusing on a lung region, a z-stack was acquired without particles. Next, the lung was ventilated with pure oxygen for several minutes, ventilation stopped for 60 to 90 seconds until the alveolar space collapsed and particles (3.8 μg/g body weight particles, [Table 1](#pone.0223339.t001){ref-type="table"}) in perfluorocarbon FC-43 (PFC) instilled through the PE-10 tubing directly into the lung.

The particles in PFC were prepared immediately before instillation as follows: an aqueous suspension of Ø 50 nm red fluorescent silica particle was emulsified in PFC by three consecutive sonication of 30 seconds each on ice, (Sonic Ruptor 250, Omni International, USA).

Z-Stacks were acquired at the indicated time points; all images were taken with Nikon NIS-Elements AR 4.20. Calculations were performed with ImageJ 1.50e and the "analyze particles" plugin. Stacks of images were merged for maximum intensity Z projection. The threshold was adjusted for the images prior to, and after, particle exposure according to Otsu \[[@pone.0223339.ref013]\], and the numbers and sizes of the agglomerates were analyzed. After background subtraction, the number and sizes of agglomerates were calculated following the initial settling at 2 minutes and every 10 minutes thereafter. For single plane analysis Renyi's Entropy threshold was applied before analyzing.

*In vivo* preparation for transmission electron microscopy {#sec005}
----------------------------------------------------------

Mice were anesthetized using 5% isoflurane and fluorescent amorphous silica particles of 50 nm or silica nanoparticles with a size of 58 nm and silver core of 28 nm were instilled into the trachea at concentrations described in [Table 1](#pone.0223339.t001){ref-type="table"}. After 1 and 24 h, mice were euthanized with 22 mg/kg pentobarbital (Ceva, France). Samples of the lower left lobe of the lung were fixed in 2.5% gluteraldehyde, 1.6% formaldehyde in 0.1 M cacodylate buffer, pH 7.4 overnight. For TiO~2~ samples were post-fixed in 1% osmium tetroxide buffered with cacodylate for 1 h for later analysis by transmission electron microscopy (TEM). After polymerization 70 nm thin vertical sections were cut from a representative area with cells (Ultracut E, Reichert-Jung, Vienna, Austria). Sections were stained with aqueous uranyl acetate and Reynolds's lead citrate and observed under a Hitachi H-7650 TEM (Hitachi) at 80 kV with an AMT16000 digital camera (Advanced Microscopy Techniques, USA).

Whole organ imaging {#sec006}
-------------------

Far-red fluorescent particles were instilled at 36 μg/g body weight. After 24 h liver, spleen and kidneys were collected. Images were acquired in a small animal imaging system (In-Vivo Xtreme 4MP, USA) at an excitation and emission wavelength of 730 and 790 nm, respectively and with a 5 seconds exposure time.

*In vitro* uptake studies {#sec007}
-------------------------

A549 (ATCC, Virginia, USA) were maintained in F12 (Gibco, USA) supplemented with 10% of fetal bovine serum (Gibco, USA), 2 mM L-Glutamine, and 10 mM Hepes (Life Technologies, Canada). 2--2.5 μg of 50 nm red fluorescent nanoparticles were added to a confluent monolayer of A549 in a 35 mm ibidi bottom dish for 1 h and then washed to remove unbound nanoparticles. Samples were then fixed and visualized by an ELYRA PS.1 inverted confocal microscope equipped with 63x 1.4NA objective (Zeiss, Germany). Stacks were recorded 0.3 μm apart from apical side to basolateral side. A representative plane near to the middle of the stack was chosen for mean fluorescence intensity (MFI) calculation and to ensure the particle was within the cell. By using imageJ MFI was calculated from five arbitrary areas within every cell and a minimum of 20 cells were counted to obtain mean fluorescence intensity/unit area (MFI/μm^2^). A minimum of four experiments were performed. Alternatively, we have also measured total fluorescence from a maximum intensity projection of all the optical sections. Both measurement strategies showed a similar result. Particle uptake for cells at the middle of the stack was quantified using the imageJ analyze particle plug-in.

Data and statistical analysis {#sec008}
-----------------------------

All experiments were performed either in triplicate or as indicated in the figure legends. The results are described as mean ± standard deviation. Statistical analysis was performed by student\'s t-test and, where applicable, p-values were adjusted according to Bonferroni for multiple comparisons. Significant levels are indicated as \* p \< 0.05, \*\* p \< 0.01, \*\*\* p \< 0.001, and \*\*\*\* p \< 0.0001. Statistical calculations and graphs were performed using either GraphPad Prism (version 5.0) or R software (version 3.5.1) \[[@pone.0223339.ref014]\] and the plot3D (version 1.1.1) package \[[@pone.0223339.ref015]\].

Results {#sec009}
=======

To investigate particle clearance from the alveolar region in situ, in real time, we employed intravital microscopy. We used perfluorocarbon (PFC) to homogenously deliver dispersed nanoparticles to the peripheral lung. PFC also improved the microscopy (see "discussion"). During the microscopy, the animals were subjected to partial-liquid ventilation, a procedure that is not harmful \[[@pone.0223339.ref016],[@pone.0223339.ref017]\].

For the microscopy, z-stacks of 60-μm depth were acquired before and directly after instillation of bright, exceptionally stable fluorescent nanoparticles ([S1H Fig](#pone.0223339.s001){ref-type="supplementary-material"}). Z-stacks were then acquird in intervals of at most ten minutes for one hour. The alveolar walls were easily identified due to their strong auto-fluorescent at 488 nm (maximum projection image, [Fig 1A](#pone.0223339.g001){ref-type="fig"}), a property previously exploited for lung imaging \[[@pone.0223339.ref018]\]. The instilled particles settled on the alveolar wall in agglomerates of variable size and shape ([Fig 1C and 1D](#pone.0223339.g001){ref-type="fig"}). Smaller agglomerates disappeared one-by-one from view whereas larger entities were gradually reduced in size ([Fig 1E and 1F](#pone.0223339.g001){ref-type="fig"}). For instance, arrows in [Fig 1D](#pone.0223339.g001){ref-type="fig"} indicate agglomerates that vanished or diminished in [Fig 1F](#pone.0223339.g001){ref-type="fig"}. Quantifying the number and area of agglomerates in the stack showed a reduction to about half after 30 minutes ([Fig 2C](#pone.0223339.g002){ref-type="fig"}), consistent with the published biokinetics for the initial phase of clearance \[[@pone.0223339.ref019]\]. A fraction of particle agglomerates remained stationary within the observation timeframe of one hour ([Fig 2C](#pone.0223339.g002){ref-type="fig"}), reflecting a second, slower phase of clearance, also found by Kreyling et al. \[[@pone.0223339.ref019]\].

![Intravital lung imaging of silica nanoparticles in mice.\
**A-F:** intravital microscopy of an alveolar region prior to instillation (A), 2 minutes after (C) and 1 h (E) after instilling Ø 50 nm red fluorescent amorphous silica particles, suspended in PFC (maximum intensity projection of a 60 μm-deep stack). The alveolar wall is auto-fluorescent in green. The particles are in agglomerates of variable size, similar to those observed by TEM ([Fig 3](#pone.0223339.g003){ref-type="fig"}). (B), (D), and (F) show the red channel only for better clarity. Agglomerates either have shrunk in size and intensity one hour after instillation, or have vanished entirely (red arrows). Note that the particles used do not photo bleach under the illumination chosen ([S1H Fig](#pone.0223339.s001){ref-type="supplementary-material"}). space bar: A-F = 20 μm shown in A.](pone.0223339.g001){#pone.0223339.g001}

![Quantification of *in vivo* silica nanoparticle clearance.\
Plot (z, t) of particles numbers (A) and area covered by particles (B) within the z-stack of [Fig 1](#pone.0223339.g001){ref-type="fig"}, over time. The stack starts with the alveolar wall close to the pleura (0 μm) and progresses towards the alveolar ducts (60 μm). Most particles are found close to the pleura (within alveoli). Particle number and area decrease within the 60 minutes time frame. The data indicates no movement from the alveoli towards the alveolar ducts, indicating that the particles do not leave the area via the airways. **C:** Quantification of particle clearance (data are mean ± SD, n = 3), with the reduction in agglomerate numbers in red and area in maximum intensity projection in blue. About half of the particles are cleared from the field of view over the first 30 minutes after exposure. The remainder of particles persist over the observation time of one hour. Significant changes are determined by student\'s t-test with Bonferroni adjusted p-values corrected for multiple comparisons (\* p \< 0.05, \*\* p \< 0.01, \*\*\* p \< 0.001, \*\*\*\* p \< 0.0001). **D:** Whole organ imaging. Overlay of a white light image of the organs and a heat map-display of the fluorescence in liver (top), spleen (middle), and kidney (bottom) 24 h after instillation of Ø 50 nm Cy-7-labelled silica particles into the lung (right). The control images (left column) shows a low level of false positive counts in the liver.](pone.0223339.g002){#pone.0223339.g002}

Next, we analyzed the z-stacks for movement of particles towards alveolar ducts over time (i.e. we analyzed whether particles agglomerates changed position within the alveolar lumen over the time of observation). This was not observed within the experimental timeframe ([Fig 2A and 2B](#pone.0223339.g002){ref-type="fig"}). Rather the agglomerates did not change their location when becoming reduced in size or before disappearing. We therefore hypothesized that the rapid phase of particle removal from the alveolar lumen occurs by crossing of the epithelium at the site of where particles have settled. Before investigating this hypothesis in mice, we tested as a control *in vitro* whether exposure to PFC affects particle interaction with the epithelium. A confluent layer of A549 alveolar epithelial cells was exposed to nanoparticles either dispersed in PFC or in media under fluorescent microscopy ([S2A Fig](#pone.0223339.s002){ref-type="supplementary-material"}). In both cases, the response of the cells to the particles was rapid endocytosis, with no significant difference between the two exposure types ([S2B Fig](#pone.0223339.s002){ref-type="supplementary-material"}). Further, we did not observe an increase of apoptotic cells under the microscope in our *in vitro* experiments.

To see if particles removed from the lung had become systemic, In-Vivo Xtreme 4MP whole-animal imaging was conducted. Results with entire animals were not achieved because of a high background against a low signal. However, after examining isolated organs, we found particle accumulation in the liver and kidneys 24 h after instillation ([Fig 2D](#pone.0223339.g002){ref-type="fig"}). This indicates that particles had become systemic. Renal- and hepatobiliary clearance has been shown for systemic silica nanoparticles, explaining their accumulation in the respective organs \[[@pone.0223339.ref006],[@pone.0223339.ref020]\].

To investigate the alveolar epithelial crossing, we instilled particles in buffer suspension into the lungs of mice, euthanized them at either 1 h or 24 h after exposure, and prepared the lower left lobes of the lungs for transmission electron microscopy (TEM). We used a range of different particles and concentrations ([Table 1](#pone.0223339.t001){ref-type="table"}). Following the 1 h exposure, nanoparticles were found in various stages of crossing the epithelium. The particles were mostly in agglomerates as described by Liu et al. \[[@pone.0223339.ref011]\] (see also [S1E](#pone.0223339.s001){ref-type="supplementary-material"}, [S1F and S1G Fig](#pone.0223339.s001){ref-type="supplementary-material"}). Agglomerates adhered to the apical side of the alveolar epithelium ([Fig 3A](#pone.0223339.g003){ref-type="fig"}), or were in the process of being internalized ([Fig 3B](#pone.0223339.g003){ref-type="fig"}). Some particles were also found entangled in the tubular myelin of surfactant ([Fig 3F](#pone.0223339.g003){ref-type="fig"}). Tubular myelin is the secretion form of pulmonary surfactant and is recognized by its fishnet appearance in TEM of lung sections. Agglomerates were also inside large, membrane-bound endosomal structures within type II epithelial cells ([Fig 3C](#pone.0223339.g003){ref-type="fig"}) and adherent to the apical- and basolateral side of alveolar type I cells ([Fig 3D](#pone.0223339.g003){ref-type="fig"}). However, they were not directly observed inside type I cells, possible because crossing of these very thin cells (of the order of a few times the diameter of the nanoparticles) is bound to be fast and unlikely to be observed by TEM. Finally, we observed particles in the lumen of pulmonary venules/arterioles ([S3A and S3B Fig](#pone.0223339.s003){ref-type="supplementary-material"}) indicating that they had crossed the endothelium to reach the blood stream. Another route for the particles to become systemic after crossing of the epithelium is via the lymph \[[@pone.0223339.ref007]\].

![Electron micrographs of lung sections after instillation of 50 nm-silica nanoparticles into the lungs of mice (3.8 μg/g body weight).\
The micrographs show the progression of the nanoparticles from the alveolar lumen across the epithelium to the interstitial region or taken up by alveolar macrophages. Particles associated with- and inside epithelial cells (A-D) are in agglomerates, whereas particles that enter macrophages are entangled in tubular myelin (F, H). **A-G: Particle movement over the first hour of exposure**. A: Particle agglomerates adhere to type II cells. B: Particles have entered type II cells into large endosomes. C: The endosome containing the particles is surrounded by a membrane. For better visibility particles of 58 nm with silver core were used. D: Particles are found on both, the apical- and the basolateral side of the of type I epithelial cells. E: Particles have entered the interstitial region. F: Particle conglomerates are also taken up by alveolar macrophages. G: At the 1 h-timepoint, 25% of type II cells contained particles within regions of the lung that were exposed, whereas less than 10% of alveolar macrophages in the same region contained particles (data are mean ± SD, from three mice per condition and three sections per mouse. Significant changes are determined by student\'s t-test (\*\*\*\* p \< 0.0001). **H, I particles after 24 h:** H: At this time point, we found no particles within alveolar epithelial cells. Particles were either in the alveolar lumen or I: inside alveolar macrophages. Particles inside macrophages and in the alveolar lumen were entangled in tubular myelin. Higher magnifications of uptake compartments with free agglomerates and with particles in a complex with tubular myelin are shown at high magnification in [S4 Fig](#pone.0223339.s004){ref-type="supplementary-material"}. space bars: A-B, F, H, I: 500 nm, C-E: 100 nm.](pone.0223339.g003){#pone.0223339.g003}

Interestingly, we also found alveolar macrophages with intracellular compartments of agglomerates ([Fig 3F](#pone.0223339.g003){ref-type="fig"}). Unlike epithelial cells, the agglomerates within macrophages were always associated with tubular myelin, suggesting that this might be required for macrophage phagocytosis ([S4A and S4B Fig](#pone.0223339.s004){ref-type="supplementary-material"}). Overall, macrophages were scarce within sections, and alveolar epithelial cells were the primary cells involved in processing of nanoparticles ([Fig 3G](#pone.0223339.g003){ref-type="fig"}). We did not observe an increase in macrophages or other inflammatory cells into the exposed lung regions or detect signs of edema or epithelial damage.

In conclusion, trans-epithelial clearance is an effective and fast path for silica nanoparticles to be removed from the lung. The process does not appear to cause lung injury.

To investigate the fate of particles that had not accessed the rapid transepithelial pathway, we exposed mice as described above and sacrificed them after 24 h. At this point, the particles overall were relatively scarce, as compared to the 1 h-time point. Remaining particles in the alveolar lumen were associated with tubular myelin. Size and morphology of the particles were no different for the 1 h- and the 24 h-timepoints, indicating that particles themselves were stable. There were no particles adherent to- or within epithelial cells ([Fig 3I](#pone.0223339.g003){ref-type="fig"}). Macrophages contained agglomerates of particles within large endocytic compartments ([Fig 3H](#pone.0223339.g003){ref-type="fig"}). These particles were always associated with tubular myelin.

For the TEM experiments, we used moderate to low particle concentrations as compared to reported mouse silica particle instillation experiments \[[@pone.0223339.ref021]\] (3.0--3.8 μg/g body weight, comparable to intravital microscopy). In addition, a dose \~20 times lower (0.15 μg/g body weight) was used to determine if the dose affects the nature of the clearance pathway. At this low dose, particles were more often found individually rather than in agglomerates. They were few and far between in TEM sections. Clearance appeared to follow the same path to the agglomerates formed at higher concentrations ([Fig 4A--4D](#pone.0223339.g004){ref-type="fig"}).

![Electron micrographs of low dose exposure (0.15 μg/g body weight) of silica nanoparticles in the lungs of mice.\
Because particles were now individual rather that in agglomerates, we used ø 58 nm silica nanoparticle with 28 nm silver core for better visibility. After 1h, the lung was fixed and the left lower lobe sectioned for visualization. **A:** Particles between the epithelium and the endothelium, **B,C:** within the interstitium, **D:** inside a microvascular endothelial cell. **E:** Percentage of the alveolar epithelial cells (AECs) and of alveolar macrophages within TEM sections of mouse lungs that contained particles (0.15 μg/g body weight). Data are mean ± SD, from three mice per condition and three sections per mouse. Significant changes are determined by student\'s t-test (\*\*\*\* p \< 0.0001). space bars: A-D = 100 nm.](pone.0223339.g004){#pone.0223339.g004}

To investigate if this pathway is relevant to other particle chemistries, we instilled TiO~2~ nanoparticles of \< 100 nm (1% Mn-doped). TiO~2~ nanoparticles have an overall low toxicity \[[@pone.0223339.ref022]\]. Histology revealed a similar transport process across the lung epithelium as for amorphous silica ([S3C Fig](#pone.0223339.s003){ref-type="supplementary-material"} and [S5A and S5B Fig](#pone.0223339.s005){ref-type="supplementary-material"}).

In summary, amorphous silica and TiO~2~ are cleared from the peripheral lung by rapidly crossing the alveolar epithelium. Alveolar macrophages internalized particles associated with tubular myelin.

Discussion {#sec010}
==========

Inhaled nanoparticles are predominantly deposited in the alveolar region \[[@pone.0223339.ref002],[@pone.0223339.ref023]\]. The current publication shows for silica and TiO~2~ that nanoparticles may effectively be transcytosed across the alveolar epithelium to be cleared from the lung. We found that particles predominantly crossed as agglomerates which may have contributed to the efficiency of this pathway. This pathway has been predicted for the particle types used here as well as many other nanoparticles. Published biokinetics for noncationic synthetic nanoparticles, ZnO~2~-, TiO~2~- and silica-, among other nanoparticles indicates rapid and effective translocation from the alveolar lumen into the bloodstream \[[@pone.0223339.ref006],[@pone.0223339.ref007]\]. Choi, et al \[[@pone.0223339.ref007]\] state:"...there is rapid transepithelial translocation of nanoparticles from the alveolar luminal surface into the septal interstitium, followed by quick translocation to the regional draining lymph nodes where further translocation into the bloodstream could occur...". A review by Oberdörster et al. \[[@pone.0223339.ref010]\] describes passage via the lymph to the lung periphery close to the pleura \[[@pone.0223339.ref024]\].

Regarding intravital lung microscopy of the particle exposure, the use of PFC proved important. Intravital lung microscopy suffers from excessive movement during ventilation and light scattering at the air-tissue interface. Another problem, the procedure limits the observable lung to a small region that cannot be changed once the microscopy has commenced. Sucessful imaging therefore depends on a homogenous and reliable deposition of particles within the field of view. Particle exposure via an aqueous bolus is not well suited for intravital microscopy because the distal region of the lung under observation is often shut off from the exposure by trapped air. Using a particle emulsion in PFC (i.e. an aqueous suspension of particles is emulsified in PFC) solved these problems. When instilled, the dispersion filled up the entire airspaces of the lower lung regions owing to its low viscosity, very low surface tension, high density (twice that of water), and immiscibility with water. In addition to reliably carrying the particles into the field of view, PFC improved the microscopy because it matches the refractive index of the alveolar lumen to the tissue to reduce light scattering. The motion of breathing was also strongly reduced and allowed us to observe nanoparticles over an extended period of time. We note that PFC preserves the airway and alveolar structure including the surfactant layer at the air-tissue interface \[[@pone.0223339.ref009]\], the thin layer of alveolar fluid and the epithelium, without causing injury or affecting gas exchange. PFC emulsions have been successful for delivery of emulsified nanoparticulate drugs to the lungs \[[@pone.0223339.ref025]\] \[[@pone.0223339.ref026]\].

What is the significance of the rapid transcytosis mechanism described in the current paper for lung homeostasis? The lung-air interface must be clear of foreign objects to ensure unobstructed air flow, gas exchange and prevent inflammation. The nasal cavity or the trachea-bronchial tree trap and remove larger particles. Nanoparticles behave increasingly like gas molecules with decreasing size and therefore bypass these defence mechanisms and settle where gas exchange occurs, in the alveolar lung. Clearance of these particles via the lymph and the blood proved highly effective for the particle types studied. Inhaled nanoparticles, while predominantly deposited in the alveolar region, may also settle in the bronchi and bronchioles. It will be interesting to see whether these particles are cleared via the mucociliary escalator like larger particles or traverse the (airway) epithelium. We note that the mucus with particles will mostly enter the gastrointestinal tract from where they potentially also can become systemic.

Not all nanoparticles follow the pathway described here and will be the subject of future studies. For example, carbon particles from coal mining or cigarette smoke \[[@pone.0223339.ref027]\] may accumulate within the alveolar lumen resulting in emphysema. Particles that accumulate in the interstitium may induce pneumoconiosis \[[@pone.0223339.ref028]\]. As well, not all particles that reach the bloodstream will be cleared without causing damage, but be responsible for cardiovascular, renal or neural effects \[[@pone.0223339.ref029]\]. Another subject that warrants more research is the detailed cell-biology of the transcytosis mechanism.

In conclusion, the current paper contributes an essential pathway that aligns with the reported kinetics of lung clearance of a broad spectrum of nanoparticles \[[@pone.0223339.ref005]--[@pone.0223339.ref007]\]. In addition to the implications for nanoparticle toxicicty, understanding of the transepithelial pathway may may be important for the design of inhaled particulate drugs, broadening the spectrum of drugs that may be delivered via the lung. Therapeutic substances may include new peptide and protein drugs, where delivery via the lungs is particularly important because of the many limitations of other delivery modes \[[@pone.0223339.ref030]--[@pone.0223339.ref032]\].

Supporting information {#sec011}
======================

###### Nanoparticle characterization.

**A:** TEM of agglomerates of ø 50 nm red fluorescently labeled silica nanoparticle used for the intravital microscopy and **B:** ø 58 nm silica nanoparticle with 28 nm silver core used for electron microscopy of mouse lungs exposed at a low dose. **C:** ø 50 nm Cy7 infrared labeled silica nanoparticles used for isolated organ imaging. **D:** 2.5 μg of red silica nanoparticles were suspended in 2 ml culture media and the agglomerates were imaged using confocal microscopy. **E-F**: Hydrodynamic radii of agglomerates of ø 50 nm silica nanoparticle dispersed in phosphate-buffered saline (PBS) at 37°C, immediately following sonication (0 minutes) and after 15 minutes at 50 μg/mL (E) and 250 μg/mL (F), showing agglomeration is time and concentration dependent. **G:** Hydrodynamic radii of agglomerates of ø 50 nm-nanoparticle dispersed in phosphate-buffered saline (PBS) at 37°C (black) and cell culture media (blue). Note that the media drives agglomeration. **H:** *In vitro*, the red fluorescent nanoparticles used for the intravital microscopy do not bleach for a similar laser exposure as used for the intravital microscopy. For comparison, a FITC-labelled particle bleaches upon a similar exposure, as shown in the reduction of mean fluorescence intensity (MFI).

(TIF)

###### 

Click here for additional data file.

###### *In vitro* nanoparticle uptake in perfluorocarbon.

**A:** Sketch of the experimental setup to study the effect of delivering nanoparticles in perfluorocarbon (PFC) to lung epithelial (A549) cells on uptake as compared to delivery of particles in media. A549 cells cultured on 35 mm dishes and exposed to nanoparticles in media (Top) or suspended in PFC (bottom). **B:** Quantification of fluorescence (MFI) after 1h nanoparticle uptake in media (control), media + NaN~3~ + 2-deoxy-D-glucose (inhibition of endocytosis), PFC, PFC & NaN~3~ + 2-deoxy-D-glucose.

(TIF)

###### 

Click here for additional data file.

###### Silica and TiO~2~ nanoparticles transported in the bloodstream.

**A-B:** Mice were instilled with Cy7, infrared nanoparticles that have been used for mouse whole organ imaging. **B: enlarged view of A showing** evidence of particles in the plasma of the bloodstream.

**C:** showing an example of a blood cell with a titanium oxide particle space bars: A & C = 500 nm, B = 100 nm

(TIF)

###### 

Click here for additional data file.

###### Particle uptake in alveolar epithelial cells vs. macrophages.

**A:** Magnification from [Fig 3B](#pone.0223339.g003){ref-type="fig"}, Electron micrographs of lung sections after instillation of 50 nm-silica nanoparticles into the lungs of mice. The particles inside an uptake compartment of type II alveolar epithelial cells are in dense agglomerates, similar to [S1A Fig](#pone.0223339.s001){ref-type="supplementary-material"}. The particles do not share the compartment with membranous structures. **B:** Magnification from [Fig 3F](#pone.0223339.g003){ref-type="fig"}. Particles inside uptake compartments of macrophages are dispersed and associated with the membranous structures of tubular myelin. **C:** Tubular myelin with entangled particles in the alveolar lumen looks like the tubular myelin with particles inside macrophages. space bars: 500 nm

(TIF)

###### 

Click here for additional data file.

###### Titanium oxide nanoparticles cross the epithelium-like silica nanoparticles.

**A-B:** Mice (n = 2) were instilled with 3.8 μg/g **body weight** 1% Mn-doped TiO~2~ (ø\<100 nm particles). **A:** shows TiO~2~ nanoparticles inside a Type II cell. **B:** shows an example of TiO~2~ nanoparticles having crossed the alveolar epithelium similar to the silica nanoparticles. space bars: A = 500 nm, B = 100 nm.

(TIF)

###### 

Click here for additional data file.

We thank W. Dong for preparation of TEM sections, K. Wojcik for helping to establish intravital microscopy, L. Gunasekara, and A. Yang for assistance in mouse experiments.

AEC

:   alveolar epithelial cells from mice

COPD

:   chronic obstructive pulmonary disease

hAEC

:   human primary alveolar epithelial cells

MFI

:   mean fluorescence intensity

PFC

:   perfluorocarbon

TEM

:   transmission electron microscopy

TGN

:   trans-Golgi network
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Dear Dr. Ganguly,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Aug 31 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Salik Hussain, D.V.M, M.S., Ph.D.,

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>
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Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state \"The authors have declared that no competing interests exist.\", as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>

 This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Ganguly et al. investigated the transcytosis of silica nanoparticles across alveolar epithelial cells. To perform these experiments they used a novel combination of techniques including intravital microscopy, TEM, whole organ imaging, and in vitro studies. The modification to inverted lung microscopy to include partial liquid ventilation to image the nanoparticles is interesting from a technical/experimental point of view. Also the use of relatively inert silica nanoparticles that have their kinetic profiles already established was a strength of the study and removed some factors such as inflammation, edema, and other toxicity that may have occurred with use of another particle type. The use of TiO2 nanoparticles was able to validate their findings from silica exposures.

Comments

1\. The materials sections states that 4 silica nanoparticle sizes were purchased. It is unclear in specific experiments which nanoparticle was utilized. For example, in the in vitro assessment of A549 cell internalization it only states the concentration not the size. Although mentioned within the materials the 30 and 500 nm nanoparticles do not appear to have been used.

2\. The characterization of the nanoparticles is sufficient and well done.

3\. The results as written include a large amount of discussion. These portions need to be moved to the discussion. As currently written the discussion is lacking in depth.

4\. Figures 2C, 3G, and 4E include graphs with error bars. These figures lack statistical analysis. Please perform statistical assessments of these data to establish if differences are significant. Also add a section into the methods detailing statistical information such as group sizes, statistical tests, and threshold of significance.

Reviewer \#2: The manuscript "In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells" by Ganguly, et al, is well-written and describes research I believe would be of interest to the readership of PLOS One. The mechanisms by which nanoscale particles move from the alveolar space to systemic circulation is not fully understood and this manuscript provides impactful insight into this topic.

I have some minor revisions I would recommend before publication in PLOS One:

1\) While the hydrodynamic diameter of the nanoparticle agglomerates formed in this study was measured for PBS and culture medium, this agglomeration size is missing for the perfluorocarbon vehicle used in the partial liquid ventilation. Given the importance of this portion of the manuscript to the conclusions being drawn, it is critical that some measure of agglomeration in PFC is made. It is not described in the methods section what device was used to measure these diameters, but the Malvern Zetasizer can also be used for organic solvents.

2\) The manuscript does not make a convincing case that significant amounts of nanomaterial are not being caught/cleared by the mucociliary escalator, especially since this method of clearance is widely established for micro-scale/fine particles. The assertion that "the particles do not leave the area via the airways" relies on the 60um z-stack in figure 2, suggesting that there are more particles in the alveolar sacs than in the ducts. However, large percentages of particle agglomerates should be getting caught in the conducting airways before they reach the alveolar ducts (as this is their purpose), and this effect would be even more pronounced in human lungs where there is more branching. The manuscript should include some discussion on the relative proportions of inhaled nanoparticle agglomerates which reach the alveolar space vs that which is cleared by the conducting airways.

3\) Related to the previous point, the clearance of particles by mucociliary action would put them into the gastrointestinal tract, providing a new potential point of entry into systemic circulation. While it is unlikely that the GI tracts of the study mice are still available for analysis, some discussion into why the authors believe that alveolar uptake is a more important contributor to systemic nanoparticle circulation than GI uptake would be warranted.

4\) Nanosilica is known to be cytotoxic and causes redox stress in most other in vitro research. It is recommended that, at the least, some measure of cytotoxicity at study doses be provided in the supplementary information. Some discussion on the justification for using the doses applied in this study (as in, comparisons to "real world" exposures) as well as why no cytotoxicity or inflammation was observed (what doses would cause these effects and are they realistic exposures?) would be helpful to establish the relevance of the manuscript.

5\) More speculatively, it is surprising to me that a "fast track" mechanism for transporting inhaled particles in bulk to the bloodstream/lymph would even exist, given how many other safeguards are in place to prevent exactly that. I am curious to hear the author's opinions on why such a mechanism might exist and what purpose this would serve the animal.

Reviewer \#3: The authors studied the mechanism of silica nanoparticles (50 nm) to get cleared by crossing the lung epithelium within 30 minutes. The authors presented fluorescence data and TEM showing the particles in transcytosis. This is an interesting observation, however, more proof is needed on this clearance pathway.

1\. Amorphous Silica has been shown to be soluble in the presence of salts and proteins, the authors should test the dissolution rate of the these nanoparticles in physiologically relevant lung fluid. This is important because fluorescent labels may be released to cause an artifact of particle clearance.

2\. More quantitative method of clearance is the ICP-MS, especially for the silica with silver cores, which could give more accurate data than fluorescence.

3\. Transcytosis is often mentioned, but rarely a detailed pathway is described. This study lacks a mechanistic understanding other than an interesting phenomenon.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Answers to reviewers: We are grateful for the insightful criticism by the reviewers and hope that we have been able to address the problems.

\-\--

Reviewer \#1: Ganguly et al. investigated the transcytosis of silica nanoparticles across alveolar epithelial cells. To perform these experiments they used a novel combination of techniques including intravital microscopy, TEM, whole organ imaging, and in vitro studies. The modification to inverted lung microscopy to include partial liquid ventilation to image the nanoparticles is interesting from a technical/experimental point of view. Also the use of relatively inert silica nanoparticles that have their kinetic profiles already established was a strength of the study and removed some factors such as inflammation, edema, and other toxicity that may have occurred with use of another particle type. The use of TiO2 nanoparticles was able to validate their findings from silica exposures.

Comments

1\. The materials sections states that 4 silica nanoparticle sizes were purchased. It is unclear in specific experiments which nanoparticle was utilized. For example, in the in vitro assessment of A549 cell internalization it only states the concentration not the size. Although mentioned within the materials the 30 and 500 nm nanoparticles do not appear to have been used.

We thank the reviewer for this important question. Indeed, we did not use the 30 and 500 nm nanoparticles in this set of experiments and we are sorry for this confusion. The material and methods section have been updated accordingly.

2\. The characterization of the nanoparticles is sufficient and well done.

Thank you.

3\. The results as written include a large amount of discussion. These portions need to be moved to the discussion. As currently written the discussion is lacking in depth.

We agree with the reviewer. We moved most of the discussion from the results- to the discussion section. We left some discussion in the results section to provide the rationale for our experimental approach.

4\. Figures 2C, 3G, and 4E include graphs with error bars. These figures lack statistical analysis. Please perform statistical assessments of these data to establish if differences are significant. Also add a section into the methods detailing statistical information such as group sizes, statistical tests, and threshold of significance.

We thank the reviewer for this comment. We now indicate statistical significance in figures 2C, 3G, and 4E and added a section into the methods describing statistical tests. It can be noted that in Figures 3G and 4E, as well as at the later time points also for figure 2C (with one exception), all differences are highly significant (p-values are \< 0.001 or \< 0.0001).

\-\--

Reviewer \#2: The manuscript "In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells" by Ganguly, et al, is well-written and describes research I believe would be of interest to the readership of PLOS One. The mechanisms by which nanoscale particles move from the alveolar space to systemic circulation is not fully understood and this manuscript provides impactful insight into this topic.

I have some minor revisions I would recommend before publication in PLOS One:

1\) While the hydrodynamic diameter of the nanoparticle agglomerates formed in this study was measured for PBS and culture medium, this agglomeration size is missing for the perfluorocarbon vehicle used in the partial liquid ventilation. Given the importance of this portion of the manuscript to the conclusions being drawn, it is critical that some measure of agglomeration in PFC is made. It is not described in the methods section what device was used to measure these diameters, but the Malvern Zetasizer can also be used for organic solvents.

We thank the reviewer for this important comment and suggestion. For intravital microscopy, an aqueous suspension of nanoparticles was emulsified in PFC. This means that the particles remained within microscopic droplets of buffer. Hence, we assume that the agglomeration is no different than for particles in aqueous suspension. As well, we note that the agglomerates are directly observed in the intravital microscope and seem to correlate with the observations made in TEM. Finally, we note that emulsion of water in PFC will scatter in DLS measurements (Malvern Zetasizer). The Zetasizer has indeed been used in the past to determine droplet size of water in PFC (Grapentin C, Barnert S, Schubert R. Monitoring the Stability of Perfluorocarbon Nanoemulsions by Cryo-TEM Image Analysis and Dynamic Light Scattering. PLOS ONE. 2015;10: e0130674. doi:10.1371/journal.pone.0130674). However, we realized that we need to clarify our methods section regarding the preparation of the emulsion as follows:

"The particles in PFC were prepared immediately before instillation as follows: an aqueous suspension of Ø 50 nm red fluorescent silica particle was emulsified in PFC by three consecutive sonication of 30 seconds each on ice, (Sonic Ruptor 250, Omni International, USA)."

Further, we have revised our manuscript to note this limitation in the Results.

2\) The manuscript does not make a convincing case that significant amounts of nanomaterial are not being caught/cleared by the mucociliary escalator, especially since this method of clearance is widely established for micro-scale/fine particles. The assertion that "the particles do not leave the area via the airways" relies on the 60um z-stack in figure 2, suggesting that there are more particles in the alveolar sacs than in the ducts. However, large percentages of particle agglomerates should be getting caught in the conducting airways before they reach the alveolar ducts (as this is their purpose), and this effect would be even more pronounced in human lungs where there is more branching. The manuscript should include some discussion on the relative proportions of inhaled nanoparticle agglomerates which reach the alveolar space vs that which is cleared by the conducting airways.

We thank the reviewer for this important set of insights. We have accommodated these suggestions by expanding the Discussion of the manuscript to better emphasize why the pathway described is important. We now point out the limitations of the current study and the problems not addressed by us.

In direct answer to the reviewer, we argue that we address an important aspect of particle clearance in the current submission. We agree that retention and clearance of particles deposited in the nasal region and the upper airways is well established for micron-sized and larger particles. They are either kept from entering the lung or are removed by the mucociliary pathway. We also agree with the reviewer that it will be interesting to see what happens to nanoparticles that deposit in this region (i.e. the degree to which they are removed via the mucociliary pathway or whether they follow a different path). However, over 50% of nanoparticles deposit in the alveolar region, depending on size (reviewed e.g. Oberdürster, Günter. \"Toxicology of ultrafine particles: in vivo studies. \"Philosophical Transactions of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences 358.1775 (2000): 2719-2740.).

We clarify this point now in the manuscript: "Inhaled nanoparticles, while predominantly deposited in the alveolar region, may also settle in the bronchi and bronchioles. It will be interesting to see whether these particles are cleared via the mucociliary escalator or traverse the (airway) epithelium."

Particles similar to the ones studied here were shown to enter the bloodstream from this region with a half-life time of about 0.5 h and were almost fully removed from the lung within 24 h (cited and discussed by us). This is incompatible with the canonical clearance mechanism for alveolar "dust" via alveolar macrophages and calls for an alternative pathway. We now show that this pathway involves crossing of the alveolar epithelium.

Regarding the 60-um z-stacks, we agree that these results do not address what happens to particles that have deposited in the airways. Rather, observations of the 60-um z-stacks indicate that particles that have deposited on the alveolar wall do not migrate towards the bronchioles. We thus exclude that the alveolar population of particles leaves via the airways. We write this now more clearly: "Next, we analyzed the z-stacks for movement of particles towards alveolar ducts over time (i.e. we analyzed whether particles agglomerates changed position within the alveolar lumen over the time of observation)."

3\) Related to the previous point, the clearance of particles by mucociliary action would put them into the gastrointestinal tract, providing a new potential point of entry into systemic circulation. While it is unlikely that the GI tracts of the study mice are still available for analysis, some discussion into why the authors believe that alveolar uptake is a more important contributor to systemic nanoparticle circulation than GI uptake would be warranted.

We have addressed this important recommendation by discussing this point in the revised manuscript as follows: "We note that the mucus with particles will mostly enter the gastrointestinal tract from where they potentially also can become systemic."

4\) Nanosilica is known to be cytotoxic and causes redox stress in most other in vitro research. It is recommended that, at the least, some measure of cytotoxicity at study doses be provided in the supplementary information. Some discussion on the justification for using the doses applied in this study (as in, comparisons to "real world" exposures) as well as why no cytotoxicity or inflammation was observed (what doses would cause these effects and are they realistic exposures?) would be helpful to establish the relevance of the manuscript.

We thank the reviewer for this important question. As indicated in our manuscript, we did not observe an increase in macrophages or other inflammatory cells into the exposed lung regions or detect signs of edema or epithelial damage. Further, we never observed any apoptotic processes with these silica nanoparticles in our in vitro cell culture experiment using the alveolar epithelial A549 cells. We now state this observation in the Results:

"Further, we did not observe an increase of apoptotic cells under the microscope in our in vitro experiments."

5\) More speculatively, it is surprising to me that a "fast track" mechanism for transporting inhaled particles in bulk to the bloodstream/lymph would even exist, given how many other safeguards are in place to prevent exactly that. I am curious to hear the author's opinions on why such a mechanism might exist and what purpose this would serve the animal.

This a fascinating question, and we have revised our manuscript to discuss this more specifically. We agree that larger inhaled particles are caught in the nasal cavity or removed via the mucociliary escalator. However, nanoparticles are preferentially deposited in the alveolar region where these defense mechanisms are not present. We argue that these particles are predominantly cleared from the lung via the bloodstream after crossing the alveolar epithelium, based on the biokinetics studies cited by us and our own study. We propose that this fast track mechanism is an important clearance mechanism for inhaled nanoparticles and possibly the main defense against some nanoparticles in the lung. We cite studies that show hepatic clearance or by urinary excretion and changed a section in the discussion to reflect this as follows:

"What is the significance of the rapid transcytosis mechanism described in the current paper for lung homeostasis? The lung-air interface must be clear of foreign objects to ensure unobstructed air flow, gas exchange and prevent inflammation. The nasal cavity or the trachea-bronchial tree trap and remove larger particles. Nanoparticles behave increasingly like gas molecules with decreasing size and therefore bypass these defence mechanisms and settle where gas exchange occurs, in the alveolar lung. Clearance of these particles via the lymph and the blood proved highly effective for the particle types studied. Inhaled nanoparticles, while predominantly deposited in the alveolar region, may also settle in the bronchi and bronchioles. It will be interesting to see whether these particles are cleared via the mucociliary escalator like larger particles or traverse the (airway) epithelium. We note that the mucus with particles will mostly enter the gastrointestinal tract from where they potentially also can become systemic.

Not all nanoparticles follow the pathway described here and will be the subject of future studies. For example, carbon particles from coal mining or cigarette smoke \[27\] may accumulate within the alveolar lumen resulting in emphysema. Particles that accumulate in the interstitium may induce pneumoconiosis \[28\]. As well, not all particles that reach the bloodstream will be cleared without causing damage, but be responsible for cardiovascular, renal or neural effects \[29\]. Another subject that warrants more research is the detailed cell-biology of the transcytosis mechanism."

\-\--

Reviewer \#3: The authors studied the mechanism of silica nanoparticles (50 nm) to get cleared by crossing the lung epithelium within 30 minutes. The authors presented fluorescence data and TEM showing the particles in transcytosis. This is an interesting observation, however, more proof is needed on this clearance pathway.

1\. Amorphous Silica has been shown to be soluble in the presence of salts and proteins, the authors should test the dissolution rate of the these nanoparticles in physiologically relevant lung fluid. This is important because fluorescent labels may be released to cause an artifact of particle clearance.

We thank the reviewer for this question. The fluorescent silica nanoparticles used for intravital microscopy contained the dye embedded covalently into the whole particle matrix, in contrast to surface-labeled spheres. We note that the particles remained stable over one hour with respect to the fluorescence signal in PBS (i.e. the duration of the intravital microscopy). This indicates that they do not photo bleach but also not dissolve either, at least not in PBS (Fig S1H). Furthermore, we note that the same particles were also used for TEM. We did not observe a noticeable change in size of these particles in vivo over time. When we compared TEM section from mice sacrificed 1 h after the exposure to sections from mice sacrificed at the 24 hours time point, we did not observe a difference in particle diameter (Figure 3). For an intuitive direct comparison, we here show an enlarged section of Fig 3F for 1-h time point and an enlarged section of Fig. 3 IH for the 24-h time point of the same particles at the same magnification. Therefore, we are confident that we can exclude relevant solubilisation of the used particles or leakage of dye from these particles during the investigated 24 hours. We state this now in the manuscript:

"Size and morphology of the particles were no different for the 1 h- and the 24 h-timepoints, indicating that particles themselves were stable."

2\. More quantitative method of clearance is the ICP-MS, especially for the silica with silver cores, which could give more accurate data than fluorescence.

We thank the reviewer for this question. We argue that a high quality standard of materials distribution within tissue is radio-labeling. This has already been done for the problem investigated and our reference to this work has been noted as a strength by another reviewer: "Also the use of relatively inert silica nanoparticles that have their kinetic profiles already established was a strength of the study and removed some factors such as inflammation, edema, and other toxicity that may have occurred with use of another particle type." While we agree that ICP-MS could give us additional information, we are convinced that following the intact particles in the lung with the different microscopic approaches permitted us to draw the presented conclusion.

3\. Transcytosis is often mentioned, but rarely a detailed pathway is described. This study lacks a mechanistic understanding other than an interesting phenomenon.

Thank you for this valuable comment. We agree that a comprehensive study of the cell biology of the transcytosis must be a next step. To address this point we have added the following section to the Discussion:

"Another subject that warrants more research is the detailed cell-biology of the transcytosis mechanism."

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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PONE-D-19-17546R1

Dear Dr. Ganguly,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Salik Hussain, D.V.M, M.S., Ph.D.,

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have adequately addressed reviewer feedback. Following revisions the manuscript is technically and statistically sound. This meets the criteria for publication in PLoS One.

Reviewer \#2: The authors have addressed the minor revisions I requested, and I recommend publication of this work in PLOS ONE.

Reviewer \#3: The authors sufficiently addressed the comments from reviewers, so now I would recommend its acceptance.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: tian xia
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